As­traZeneca bails on rox­adu­s­tat’s fu­ture in the US, but keeps Chi­na pact with Fi­bro­Gen

As­traZeneca is hand­ing back US and cer­tain oth­er re­gion­al rights for rox­adu­s­tat to Fi­bro­Gen, end­ing a two-and-a-half-year lim­bo that fol­lowed an FDA re­jec­tion of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER